Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
BUSINESS
Pfizer Gets Breast, Ovarian Cancer Nod for Avastin Biosimilar
Pfizer Japan said on August 28 that it has grabbed additional indications for its Avastin (bevacizumab) biosimilar for the treatment of “inoperable or relapsed breast cancer” and “ovarian cancer.”Bevacizumab BS Intravenous Infusion 100 mg/400 mg “Pfizer” was rolled out in…
To read the full story
Related Article
- Pfizer Seeks Breast Cancer Use for Avastin Biosimilar
November 24, 2022
- Pfizer Rolls Out Japan’s 1st Avastin Biosimilar
December 10, 2019
BUSINESS
- Gilead Names Andrew Hexter as Japan President
April 2, 2026
- Santen Sets May Launch Date for Upneeq as Non-Reimbursed Drug
April 2, 2026
- Shionogi Completes ViiV Stake Increase to 21.7%
April 2, 2026
- Kei Kaneda Becomes President of Moderna Japan
April 2, 2026
- Human Judgment Still Key in the AI Era, Pharma Leaders Tell New Recruits
April 2, 2026
Japan will overhaul its R&D tax credit regime in its FY2026 reform, introducing a new strategic category alongside existing frameworks.…
Strategic Talent Acquisition in the Japanese Life Sciences Sector: Your Market Intelligence Briefing
Focus: How to Get the Talent You Need in a Tough MarketThe Japanese life sciences sector presents a challenging landscape for global companies. To succeed, you must move beyond reactive hiring and adopt a truly strategic talent acquisition model. Our…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…